Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
| Autor: | Bussenius J; Exelixis, 210 E. Grand Avenue, South San Francisco, CA 94080, USA. jbusseni@exelixis.com, Anand NK, Blazey CM, Bowles OJ, Bannen LC, Chan DS, Chen B, Co EW, Costanzo S, DeFina SC, Dubenko L, Engst S, Franzini M, Huang P, Jammalamadaka V, Khoury RG, Kim MH, Klein RR, Laird D, Le DT, Mac MB, Matthews DJ, Markby D, Miller N, Nuss JM, Parks JJ, Tsang TH, Tsuhako AL, Wang Y, Xu W, Rice KD |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 Mar 15; Vol. 22 (6), pp. 2283-6. Date of Electronic Publication: 2012 Feb 02. |
| DOI: | 10.1016/j.bmcl.2012.01.105 |
| Abstrakt: | The 70-kDa ribosomal protein S6 kinase (p70S6K) is part of the PI3K/AKT/mTOR pathway and has been implicated in cancer. High throughput screening versus p70S6K led to the identification of aminopyrimidine 3a as active inhibitor. Lead optimization of 3a resulted in highly potent, selective, and orally bioavailable pyrazolopyrimidines. In this manuscript we report the structure-activity relationship of this series and pharmacokinetic, pharmacodynamic, and efficacy data of the lead compound 13c. (Copyright © 2012 Elsevier Ltd. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect